TargetMol

Pranlukast

Product Code:
 
TAR-T0694
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0694-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0694-25mg25mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0694-50mg50mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0694-100mg100mg£143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0694-200mg200mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
CAS:
103177-37-3
Formula:
C27H23N5O4
Molecular Weight:
481.512
Pathway:
Immunology/Inflammation; GPCR/G Protein; NF-κb; ; Apoptosis
Purity:
0.9985
SMILES:
O=C(Nc1cccc2c1oc(cc2=O)-c1nnn[nH]1)c1ccc(OCCCCc2ccccc2)cc1
Target:
Leukotriene Receptor; IL Receptor; TNF; NF-κB; LTR

References

1. Ichiyama T, et al. Clin Exp Allergy,2003, 33(6), 802-807. 2. Liu YC, et al. Br J Pharmacol,1998, 124(3), 563-571. 3. Ishinaga H, et al. Pharmacology,2005, 73(2), 89-96. 4. Yu GL, et al. Brain Res. 2005 Aug 16;1053(1-2):116-25. 5. Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating na?ve Bayesian classification, molecular docking and drug screening approaches[J]. RSC Advances. 2018 Jan 8(10): 5286-5297.